239 related articles for article (PubMed ID: 28297622)
41. AACR precision medicine series: Highlights of the integrating clinical genomics and cancer therapy meeting.
Maggi E; Montagna C
Mutat Res; 2015 Dec; 782():44-51. PubMed ID: 26554403
[TBL] [Abstract][Full Text] [Related]
42. Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker.
Beckman RA; Antonijevic Z; Kalamegham R; Chen C
Clin Pharmacol Ther; 2016 Dec; 100(6):617-625. PubMed ID: 27509351
[TBL] [Abstract][Full Text] [Related]
43. Personalizing Precision Oncology Clinical Trials in Latin America: An Expert Panel on Challenges and Opportunities.
Arai RJ; Guindalini RSC; Llera AS; O'Connor JM; Muller B; Lema M; Freitas HC; Soria T; Delgado L; Landaverde D; Montenegro P; Riechelmann RP
Oncologist; 2019 Aug; 24(8):e709-e719. PubMed ID: 30910864
[TBL] [Abstract][Full Text] [Related]
44. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.
Sicklick JK; Fanta PT; Shimabukuro K; Kurzrock R
Cancer Metastasis Rev; 2016 Jun; 35(2):263-75. PubMed ID: 26857926
[TBL] [Abstract][Full Text] [Related]
45. Implementing precision cancer medicine in the genomic era.
Chen HZ; Bonneville R; Roychowdhury S
Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
[TBL] [Abstract][Full Text] [Related]
46. Methodological and practical challenges for personalized cancer therapies.
Wistuba II; Gelovani JG; Jacoby JJ; Davis SE; Herbst RS
Nat Rev Clin Oncol; 2011 Mar; 8(3):135-41. PubMed ID: 21364686
[TBL] [Abstract][Full Text] [Related]
47. Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.
Ang JE; Kaye S; Banerji U
Curr Drug Targets; 2012 Nov; 13(12):1525-34. PubMed ID: 22974395
[TBL] [Abstract][Full Text] [Related]
48. Cancer Treatment in the Genomic Era.
Doherty GJ; Petruzzelli M; Beddowes E; Ahmad SS; Caldas C; Gilbertson RJ
Annu Rev Biochem; 2019 Jun; 88():247-280. PubMed ID: 30901264
[TBL] [Abstract][Full Text] [Related]
49. Precision Oncology Decision Support: Current Approaches and Strategies for the Future.
Kurnit KC; Dumbrava EEI; Litzenburger B; Khotskaya YB; Johnson AM; Yap TA; Rodon J; Zeng J; Shufean MA; Bailey AM; Sánchez NS; Holla V; Mendelsohn J; Shaw KM; Bernstam EV; Mills GB; Meric-Bernstam F
Clin Cancer Res; 2018 Jun; 24(12):2719-2731. PubMed ID: 29420224
[TBL] [Abstract][Full Text] [Related]
50. Personalized cancer genomics: the road map to clinical implementation.
Yousef GM
Clin Chem; 2012 Apr; 58(4):661-3. PubMed ID: 22322979
[No Abstract] [Full Text] [Related]
51. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
Do K; O'Sullivan Coyne G; Chen AP
Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
[TBL] [Abstract][Full Text] [Related]
52. Better Outcomes with Precision Medicine.
Cancer Discov; 2016 Dec; 6(12):1296-1297. PubMed ID: 27784709
[TBL] [Abstract][Full Text] [Related]
53. Clinical tumor sequencing: opportunities and challenges for precision cancer medicine.
Damodaran S; Berger MF; Roychowdhury S
Am Soc Clin Oncol Educ Book; 2015; ():e175-82. PubMed ID: 25993170
[TBL] [Abstract][Full Text] [Related]
54. American Society of Clinical Oncology policy statement: oversight of clinical research.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
[TBL] [Abstract][Full Text] [Related]
55. Biomarker-driven patient selection for early clinical trials.
Dienstmann R; Rodon J; Tabernero J
Curr Opin Oncol; 2013 May; 25(3):305-12. PubMed ID: 23493192
[TBL] [Abstract][Full Text] [Related]
56. Impact of a Clinical Genomics Program on Trial Accrual for Targeted Treatments: Practical Approach Overcoming Barriers to Accrual for Underserved Patients.
Farhangfar CJ; Scarola GT; Morris VA; Farhangfar F; Dumas K; Symanowski J; Hwang JJ; Mileham KF; Carrizosa DR; Naumann RW; Livasy C; Kim ES; Raghavan D
JCO Clin Cancer Inform; 2022 Jul; 6():e2200011. PubMed ID: 35839431
[TBL] [Abstract][Full Text] [Related]
57. Current Challenges in Cancer Treatment.
Zugazagoitia J; Guedes C; Ponce S; Ferrer I; Molina-Pinelo S; Paz-Ares L
Clin Ther; 2016 Jul; 38(7):1551-66. PubMed ID: 27158009
[TBL] [Abstract][Full Text] [Related]
58. Impact of the biomarker enrichment strategy in drug development.
Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
[TBL] [Abstract][Full Text] [Related]
59. Ovarian cancer: genomic analysis.
Wei W; Dizon D; Vathipadiekal V; Birrer MJ
Ann Oncol; 2013 Dec; 24 Suppl 10(Suppl 10):x7-15. PubMed ID: 24265410
[TBL] [Abstract][Full Text] [Related]
60. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
